For frail elderly patients, it's crucial to discern if poor performance status stems from disease or comorbidities. A practical approach is to initiate treatment with biologic agents alone. If the patient's status improves, it confirms the cancer is the cause, justifying the subsequent, careful addition of cytotoxic chemotherapy.
To manage the significant diarrhea associated with the new drug zanidatumab, a proactive approach is critical. The successful HORIZON-GEA trial protocol included mandatory loperamide twice daily for the first seven days of cycle one, a strategy which effectively managed toxicity without leading to treatment discontinuation.
Despite a study showing a minor hazard ratio benefit for a FLOT-like regimen over FOLFOX in the metastatic setting, experts advise against it. The significant increase in toxicity outweighs the small efficacy advantage, especially in symptomatic metastatic patients who are often nutritionally deficient and less able to tolerate aggressive chemotherapy.
Even when a new drug like zanidatumab is proven superior, experienced clinicians are reluctant to use it on their most frail or borderline-performance patients immediately. They prefer to gain real-world experience managing its side effects in more robust individuals before expanding use to these more complex cases.
For fit patients with technically stage IV gastroesophageal cancer but limited disease (e.g., only non-regional lymph nodes), a curative-intent approach is viable. This involves initial systemic biomarker-driven therapy, followed by multidisciplinary reassessment and potential consolidation with radiation or surgery on any residual disease sites.
Unlike trastuzumab, zanidatumab's effectiveness in the HORIZON-GEA-01 trial did not seem to depend on PD-L1 status. This surprising finding suggests a novel, possibly immune-mediated, mechanism of action that could expand its use to a broader patient population, including those who are PD-L1 negative.
As a practical standard of care for elderly patients, one clinician universally avoids the 5-FU bolus in metastatic settings and reduces the oxaliplatin dose in the FOLFOX regimen from 85 mg/m² to 65 mg/m² for most patients over age 75. This adjustment balances efficacy with improved tolerability in a more vulnerable population.